Which generation of targeted drugs does the NTRK inhibitor larotinib belong to?

In the field of tumor treatment, targeted drugs have gradually emerged with their precise treatment methods, and Larotrectinib (Larotrectinib), as one of the leaders, has attracted widespread attention. With its unique mechanism, this drug can accurately target tumor patients carrying NTRK (neurotrophic tyrosine receptor kinase) gene fusions, opening a new era of gene-driven "pan-cancer" treatment.

However, larotrectinib is not clearly classified in the traditional generational division of targeted drugs. This is mainly due to its unique target - TRK. The exploration of this new field makes the traditional generation system based on target and development time seem inadequate. But if we look at it from the perspective of TRK inhibitors, larotrectinib can undoubtedly be regarded as a first-generation drug in this field.

Larotrectinib effectively blocks the proliferation and metastasis of tumor cells caused by NTRK gene fusion by precisely inhibiting the activity of TRK protein. This mechanism allows it to show significant efficacy in the treatment of various cancers. Whether it is lung cancer, sarcoma, thyroid cancer, breast cancer, colorectal cancer, etc., larotrectinib can exert its therapeutic effect and is not limited by the source of the tumor tissue.

As the world's firstTRK inhibitor, the emergence of larotrectinib undoubtedly marks a major leap in the field of precision medicine. Different from the traditional "cancer type-oriented"treatment, larotrectinib brings new treatment hope to patients with its "gene target"-oriented treatment concept.

Although the efficacy of larotrectinib is significant, its long-term effects and drug resistance management still require further research and exploration. With the subsequent development and competition of similar drugs, the field of TRK inhibitors is expected to form a more complete generational classification in the future. Larotrectinib, as a pioneer in this field, will undoubtedly be forever engraved in the history of tumor treatment, opening up a new path for latecomers.

xa0

Reference materials:

1.FDADrug Description:https://www.fda.gov

2.PubMedLiterature:https://pubmed.ncbi.nlm.nih.gov/

3.NMPADrug information:https://www.nmpa.gov.cn